Back to School: How biopharma can reboot drug development. Access exclusive analysis here
The companies mutually terminated their previously announced merger, under which PEB was to acquire nucleic acid
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury